AS
BTAI icon

Altshuler Shaham’s BioXcel Therapeutics BTAI Stock Holding History

Altshuler Shaham’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,523
Closed -$744K – 545
2021
Q3 		$744K Sell
1,523
-15,606
-91% -$6.86M 0.01% 183
2021
Q2 		$7.96M Buy
+17,129
New +$9.34M 0.06% 82

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Altshuler Shaham's BTAI Position: Q4 2021 in Review

Altshuler Shaham sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 1,523 shares — an estimated $744K sold.

Altshuler Shaham first reported a position in BTAI in Q2 2021 and held it in 2 quarters. The position peaked at $7.96M in Q2 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Altshuler Shaham reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Altshuler Shaham sold 1,523 BioXcel Therapeutics shares in Q4 2021, an estimated $744K.
  • Altshuler Shaham first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 2 quarters.
  • Altshuler Shaham's BioXcel Therapeutics position peaked at $7.96M in Q2 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Altshuler Shaham's 13F filing for Q4 2021, filed 15 Feb 2022.